Blenoxane Related Published Studies
Well-designed clinical trials related to Blenoxane (Bleomycin)
Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. [2008.01.20]
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. [2007.08.10]
Patterns of failure in patients with locally advanced head and neck cancer treated postoperatively with irradiation or concomitant irradiation with Mitomycin C and Bleomycin. [2007.03.01]
Bleomycin tattooing as a promising therapeutic modality in large keloids and hypertrophic scars. [2006.08]
Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma. [2005.08]
[Therapeutic effect and pathology changing of eyelid xanthelasma by Bleomycin A5] [2005.03]
Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). [2005.02]
Inoperable oropharyngeal carcinoma treated with concomitant irradiation, mitomycin C and bleomycin - long term results. [2005]
Well-designed clinical trials possibly related to Blenoxane (Bleomycin)
Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma. [2008.07.22]
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. [2008.04]
Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). [2008.01.01]
A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). [2007.11.15]
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. [2007.11.08]
Treatment planning and delivery of involved field radiotherapy in advanced Hodgkin's disease: results from a questionnaire-based audit for the UK Stanford V regimen vs ABVD clinical trial quality assurance programme (ISRCTN 64141244). [2007.10]
Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte. [2007.07.01]
Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. [2007.07]
Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). [2007.05]
Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). [2007.04]
Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. [2007.02]
Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. [2007.02]
Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. [2007.01.20]
Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. [2007.01.01]
The expression of Ki-67 and Bcl-2 in Hodgkin's lymphoma: correlation with the International Prognostic Score and bulky disease: a study by the Serbian Lymphoma Study Group (SLG). [2007]
Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer. [2006.12.01]
Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. [2006.07.01]
Evaluation of glutathione S-transferase polymorphisms and mutagen sensitivity as risk factors for the development of second primary tumors in patients previously diagnosed with early-stage head and neck cancer. [2006.06.15]
Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). [2006.06.15]
POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group. [2006.06]
Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study. [2006.04]
The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL). [2006.04]
A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma. [2006.03.27]
MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors. [2006.01.15]
Surgery and chemotherapy versus chemotherapy as treatment of high-grade MALT gastric lymphoma. [2006]
Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin's lymphoma patients: a prospective randomized GEMOH report. [2006]
Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). [2005.12.20]
ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. [2005.12.20]
Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG. [2005.12]
Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group. [2005.11.01]
A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma. [2005.09.01]
Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. [2005.07.20]
Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. [2005.07]
Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy. [2005.04]
[Clinical randomized comparative trial of ProMACE-CytaBOM regimen and CHOP regimen in treating non-Hodgkin's lymphoma] [2005.04]
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. [2005.03.24]
A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). [2005.01]
Other research related to Blenoxane (Bleomycin)
Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor. [2008.10]
INHIBITORY EFFECT OF EMODIN ON BLEOMYCIN-INDUCED PULMONARY FIBROSIS IN MICE. [2008.09.10]
Lung fibrosis 10 years after cessation of bleomycin therapy. [2008.09]
Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. [2008.08.20]
Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. [2008.08]
Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor. [2008.08]
Role of Rac1 in a bleomycin-induced scleroderma model using fibroblast-specific Rac1-knockout mice. [2008.07]
Reversibility of the effects of subchronic exposure to the cancer chemotherapeutics bleomycin, etoposide, and cisplatin on spermatogenesis, fertility, and progeny outcome in the male rat. [2008.07]
Metastases following biopsy of oral carcinoma in hamsters and the role of local prebiopsy bleomycin. [2008.07]
Fibroproliferation in LPS-induced airway remodeling and bleomycin-induced fibrosis share common patterns of gene expression. [2008.07]
Bleomycin in Dermatology: A Review of Intralesional Applications. [2008.06.27]
Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. [2008.06.20]
Diallyl sulfide attenuates bleomycin-induced pulmonary fibrosis: critical role of iNOS, NF-kappaB, TNF-alpha and IL-1beta. [2008.06.06]
[Influence of Feixian Formula on serum transforming growth factor-beta1 and platelet-derived growth factor in rats with bleomycin-induced pulmonary fibrosis.] [2008.06]
Semiquantitative measurement of murine bleomycin-induced lung fibrosis in in vivo and postmortem conditions using microcomputed tomography: correlation with pathologic scores--initial results. [2008.06]
[Perindopril and losartan attenuate bleomycin A5-induced pulmonary fibrosis in rats] [2008.06]
[Effects of curcumin on bleomycin-induced damages in pulmonary functions in rats] [2008.06]
Aerosolized STAT1 antisense oligodeoxynucleotides decrease the concentrations of inflammatory mediators in bronchoalveolar lavage fluid in bleomycin-induced rat pulmonary fibrosis. [2008.06]
Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors. [2008.05]
Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer. [2008.04.10]
Mouse model of dermal fibrosis induced by one-time injection of bleomycin-poly(L-lactic acid) microspheres. [2008.04]
Increased sensitivity to bleomycin in upper aerodigestive tract mucosa of head and neck squamous cell carcinoma patients. [2008.03.29]
Effectiveness of etanercept in bleomycin-induced experimental scleroderma. [2008.02]
Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. [2008.01.29]
Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin's lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin's Lymphoma Study Group. [2008.01.01]
Induction of complete and incomplete chromosome aberrations by bleomycin in human lymphocytes. [2008.01.01]
Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis. [2008.01]
Intratumoral bleomycin and IL-12 electrochemogenetherapy for treating head and neck tumors in dogs. [2008]
Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor. [2008]
Relationships between early inflammatory response to bleomycin and sensitivity to lung fibrosis: a role for dipeptidyl-peptidase I and tissue inhibitor of metalloproteinase-3? [2007.12.01]
Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy. [2007.12]
Bleomycin-induced pulmonary fibrosis is attenuated by a monoclonal antibody targeting HER2. [2007.12]
[Apoptosis of type II alveolar epithelial cell induced by bleomycin in lung fibrotic rat] [2007.12]
FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin's disease--a useful tool for monitoring pulmonary toxicity and disease activity. [2007.11]
Neoadjuvant bleomycin, etoposide, and cisplatin in adult neuroblastoma arising from the broad ligament of the uterus. [2007.11]
[Effects of feixianping on collagen type I and III in bleomycin induced pulmonary fibrosis rats] [2007.11]
[Neoadjuvant and adjuvant chemotherapy with methotrexate, cisplatin and bleomycin for advanced penile cancer: a case report] [2007.11]
Preventive effect of hochu-ekki-to, a Japanese herbal medicine, on bleomycin-induced lung injury in mice. [2007.11]
Bleomycin-induced flagellate dermatitis. [2007.11]
Neuroradiological findings of bleomycin leakage in cystic craniopharyngioma. Report of three cases. [2007.10]
Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. [2007.09.15]
Treatment with chondroitinase ABC alleviates bleomycin-induced pulmonary fibrosis. [2007.09]
[Effects of bone marrow mesenchymal stem cells on bleomycin induced pulmonary fibrosis in rats] [2007.09]
Effect of intramuscular injection of hepatocyte growth factor plasmid DNA with electroporation on bleomycin-induced lung fibrosis in rats. [2007.08.20]
Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy. [2007.08]
Effects of extremely low-frequency electromagnetic fields on delayed chromosomal instability induced by bleomycin in normal human fibroblast cells. [2007.08]
Compared therapeutic efficacy between intralesional bleomycin and cryotherapy for common warts: a randomized clinical trial. [2007.07.13]
Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial. [2007.07.02]
Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. [2007.07.01]
Bleomycin treatment for verrucae. [2007.07]
Influence of early neutrophil depletion on MMPs/TIMP-1 balance in bleomycin-induced lung fibrosis. [2007.07]
Glycogen synthase kinase-3beta inhibition attenuates the development of bleomycin-induced lung injury. [2007.07]
Resistance of fibrogenic responses to glucocorticoid and 2-methoxyestradiol in bleomycin-induced lung fibrosis in mice. [2007.07]
Increased pulmonary FDG uptake in bleomycin-associated pneumonitis. [2007.06]
Investigation of the effects of alpha-tocopherol on the levels of Fe, Cu, Zn, Mn, and carbonic anhydrase in rats with bleomycin-induced pulmonary fibrosis. [2007.06]
Therapeutic effects of alpha-lipoic acid on bleomycin-induced pulmonary fibrosis in rats. [2007.06]
|
